Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections

Kenji Tabata, Masataka Katashima, Akio Kawamura, Yusuke Tanigawara, Keisuke Sunagawa

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The objective of this study was to propose the appropriate dosage regimen of micafungin for pediatric use, considering the effects of dose-linearity, age and other cofactors on the pharmacokinetics. Pharmacokinetic analysis of micafungin and its active metabolites (M1 and M2) after intravenous infusion at doses of 1 to 3 mg/kg was conducted for 19 Japanese pediatric patients (3 infants, 7 toddlers, and 9 pupils) with deep mycosis caused by either Aspergillus or Candida species. One patient was given the maximum dose of 6 mg/kg. The Cmax of micafungin increased in proportion to the dose. The mean values (S.D.) were 5.03 (2.33), 10.25 (4.45), 14.8 (5.52) and 21.1 μg/ml at 1, 2 , 3 and 6 mg/kg, respectively. These parameters were comparable to those seen in adults when the parameter was normalized by body weight. The elimination half life (t1/2) of micafungin over the dose range was apparently constant with the value of 13.1 h. There was no difference between the age groups observed. In fact, the metabolite concentrations were almost the same as those obtained for non-pediatric patients. Thus, micafungin showed the same dose-proportional pharmacokinetics in pediatric patients as it did in adults. No age dependent pharmacokinetics were observed in this study. It was concluded that the body weight adjustment was adequate for the treatment of micafungin in pediatric patients.

Original languageEnglish
Pages (from-to)1706-1711
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume29
Issue number8
DOIs
Publication statusPublished - 2006

Fingerprint

Mycoses
Pharmacokinetics
Pediatrics
Body Weight
Aspergillus
Pupil
Candida
Intravenous Infusions
Half-Life
micafungin
Age Groups

Keywords

  • Fungal infection
  • Metabolite
  • Micafungin
  • Pediatric patient
  • Pharmacokinetics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections. / Tabata, Kenji; Katashima, Masataka; Kawamura, Akio; Tanigawara, Yusuke; Sunagawa, Keisuke.

In: Biological and Pharmaceutical Bulletin, Vol. 29, No. 8, 2006, p. 1706-1711.

Research output: Contribution to journalArticle

Tabata, Kenji ; Katashima, Masataka ; Kawamura, Akio ; Tanigawara, Yusuke ; Sunagawa, Keisuke. / Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections. In: Biological and Pharmaceutical Bulletin. 2006 ; Vol. 29, No. 8. pp. 1706-1711.
@article{ed81f580c64b41c6bfc136899cca1a68,
title = "Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections",
abstract = "The objective of this study was to propose the appropriate dosage regimen of micafungin for pediatric use, considering the effects of dose-linearity, age and other cofactors on the pharmacokinetics. Pharmacokinetic analysis of micafungin and its active metabolites (M1 and M2) after intravenous infusion at doses of 1 to 3 mg/kg was conducted for 19 Japanese pediatric patients (3 infants, 7 toddlers, and 9 pupils) with deep mycosis caused by either Aspergillus or Candida species. One patient was given the maximum dose of 6 mg/kg. The Cmax of micafungin increased in proportion to the dose. The mean values (S.D.) were 5.03 (2.33), 10.25 (4.45), 14.8 (5.52) and 21.1 μg/ml at 1, 2 , 3 and 6 mg/kg, respectively. These parameters were comparable to those seen in adults when the parameter was normalized by body weight. The elimination half life (t1/2) of micafungin over the dose range was apparently constant with the value of 13.1 h. There was no difference between the age groups observed. In fact, the metabolite concentrations were almost the same as those obtained for non-pediatric patients. Thus, micafungin showed the same dose-proportional pharmacokinetics in pediatric patients as it did in adults. No age dependent pharmacokinetics were observed in this study. It was concluded that the body weight adjustment was adequate for the treatment of micafungin in pediatric patients.",
keywords = "Fungal infection, Metabolite, Micafungin, Pediatric patient, Pharmacokinetics",
author = "Kenji Tabata and Masataka Katashima and Akio Kawamura and Yusuke Tanigawara and Keisuke Sunagawa",
year = "2006",
doi = "10.1248/bpb.29.1706",
language = "English",
volume = "29",
pages = "1706--1711",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "8",

}

TY - JOUR

T1 - Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections

AU - Tabata, Kenji

AU - Katashima, Masataka

AU - Kawamura, Akio

AU - Tanigawara, Yusuke

AU - Sunagawa, Keisuke

PY - 2006

Y1 - 2006

N2 - The objective of this study was to propose the appropriate dosage regimen of micafungin for pediatric use, considering the effects of dose-linearity, age and other cofactors on the pharmacokinetics. Pharmacokinetic analysis of micafungin and its active metabolites (M1 and M2) after intravenous infusion at doses of 1 to 3 mg/kg was conducted for 19 Japanese pediatric patients (3 infants, 7 toddlers, and 9 pupils) with deep mycosis caused by either Aspergillus or Candida species. One patient was given the maximum dose of 6 mg/kg. The Cmax of micafungin increased in proportion to the dose. The mean values (S.D.) were 5.03 (2.33), 10.25 (4.45), 14.8 (5.52) and 21.1 μg/ml at 1, 2 , 3 and 6 mg/kg, respectively. These parameters were comparable to those seen in adults when the parameter was normalized by body weight. The elimination half life (t1/2) of micafungin over the dose range was apparently constant with the value of 13.1 h. There was no difference between the age groups observed. In fact, the metabolite concentrations were almost the same as those obtained for non-pediatric patients. Thus, micafungin showed the same dose-proportional pharmacokinetics in pediatric patients as it did in adults. No age dependent pharmacokinetics were observed in this study. It was concluded that the body weight adjustment was adequate for the treatment of micafungin in pediatric patients.

AB - The objective of this study was to propose the appropriate dosage regimen of micafungin for pediatric use, considering the effects of dose-linearity, age and other cofactors on the pharmacokinetics. Pharmacokinetic analysis of micafungin and its active metabolites (M1 and M2) after intravenous infusion at doses of 1 to 3 mg/kg was conducted for 19 Japanese pediatric patients (3 infants, 7 toddlers, and 9 pupils) with deep mycosis caused by either Aspergillus or Candida species. One patient was given the maximum dose of 6 mg/kg. The Cmax of micafungin increased in proportion to the dose. The mean values (S.D.) were 5.03 (2.33), 10.25 (4.45), 14.8 (5.52) and 21.1 μg/ml at 1, 2 , 3 and 6 mg/kg, respectively. These parameters were comparable to those seen in adults when the parameter was normalized by body weight. The elimination half life (t1/2) of micafungin over the dose range was apparently constant with the value of 13.1 h. There was no difference between the age groups observed. In fact, the metabolite concentrations were almost the same as those obtained for non-pediatric patients. Thus, micafungin showed the same dose-proportional pharmacokinetics in pediatric patients as it did in adults. No age dependent pharmacokinetics were observed in this study. It was concluded that the body weight adjustment was adequate for the treatment of micafungin in pediatric patients.

KW - Fungal infection

KW - Metabolite

KW - Micafungin

KW - Pediatric patient

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=33746728876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746728876&partnerID=8YFLogxK

U2 - 10.1248/bpb.29.1706

DO - 10.1248/bpb.29.1706

M3 - Article

C2 - 16880629

AN - SCOPUS:33746728876

VL - 29

SP - 1706

EP - 1711

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 8

ER -